In this scenario for patients with KIR-ligands present, this effective immunotherapy combination of BEMPEG plus nivolumab may take advantage of these licensed NK cells to overcome the inhibitory signaling from KIR/KIR-ligand interactions that may be present within the TME, such that NK cells can have persistent responses to reduce the tumor burden. Here, KIR3DL1 is linked to neoplasm.